OurPipeline
AdvancingmultipleindicationswithoursdRNAplatformtechnology
DevelopmentPipeline
Advancing multiple therapeutic programs across ophthalmology, dermatology, and systemic diseases
Discovery
Preclinical
Phase I
Phase II
Phase III
Ophthalmology
Persistent Corneal Epithelial Defect (PCED)
Glaucoma
Ocular Surface Disease
Retinal Disorders
Dermatology
Wound Healing
Other
Systemic Fibrotic Disorders
Discovery
Preclinical
Clinical Stages
MarketOpportunity
Global Impact
0B+
People with Vision Impairment Globally
$0B
Projected Ophthalmic Market by 2030
0+
Addressable Disease Indications
Platform Expansion
- 50+ diseases in the ocular anterior segment alone
- 12.5M patients with ocular surface disease
- Retinal disease opportunities: Retinopathy of Prematurity, wAMD, Sub-retinal Fibrosis